U.S. Stock News

NYSE:KRC
NYSE:KRCOffice REITs

Is Kilroy Realty (KRC) A Bargain Following Its CFO Departure?

Kilroy Realty (KRC) is back in focus after the company announced the departure of Chief Financial Officer and Executive Vice President Jeffrey Kuehling on August 11, 2026, and appointed Eliott Trencher as interim principal financial officer. See our latest analysis for Kilroy Realty. The executive change follows a mixed period for Kilroy Realty’s stock, with a 30 day share price return down 10.16% and a 3 year total shareholder return of 27.11%, indicating that longer term holders have...
NasdaqGS:MLYS
NasdaqGS:MLYSBiotechs

Does New CMO Hire and Heavier Leverage Reshape the Bull Case For Mineralys Therapeutics (MLYS)?

In August 2026, Mineralys Therapeutics reported a second-quarter net loss of US$241.07 million and a six-month net loss of US$280.41 million, while also appointing veteran cardiologist and drug developer James J. “Terry” Ferguson III, M.D., as its new Chief Medical Officer with his predecessor moving into a full-time advisory role. These developments came as the company advanced its lead therapy lorundrostat toward an expected FDA decision and bolstered its balance sheet with US$150 million...
NYSE:WSO
NYSE:WSOTrade Distributors

Is Watsco (WSO) Still Undervalued As Its Share Price Pullback Tests Conviction?

Watsco (WSO) continues to attract attention after recent share price moves, with the stock closing at US$313.65. Investors are weighing this level against its value score of 4 and broader return history. See our latest analysis for Watsco. Recent trading has been choppy for Watsco, with a 1-day share price return of 0.57%, a 30-day share price return that is down 15.67%, and a 1-year total shareholder return that is down 23.74%. This points to fading momentum despite a positive 5-year total...
NYSE:TRGP
NYSE:TRGPOil and Gas

US Stock Market Today: S&P 500 Futures Slip On Bond Rout And Tech Weakness

The Morning Bull - US Market Morning Update Wednesday, Aug, 19 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.5% and Nasdaq-100 futures weaker by more than 1%. The main drag is a global bond selloff, as the US 10 year yield moves near 4.7% and France and Germany see their own 10 year borrowing costs reach multi year highs. Higher yields mean governments and companies face steeper interest bills, which can pressure stock valuations. At the...
NYSE:SM
NYSE:SMOil and Gas

SM Energy (SM) Rises With Oil Price Fears, Is It Still Cheap?

SM Energy (SM) has been in focus after its stock moved in step with a jump in crude prices, as investors reacted to rising geopolitical risk linked to Iran and concerns about potential supply disruptions. See our latest analysis for SM Energy. Those geopolitical shocks have come on top of a busy few weeks for SM Energy, which has reported higher second quarter revenue and net income, updated its 2026 production guidance, continued buying back shares, and prepared to redeem US$417 million of...
NasdaqGS:DFTX
NasdaqGS:DFTXPharmaceuticals

Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results

Definium Therapeutics (DFTX) reported positive topline Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder, with the study meeting its primary and key secondary efficacy endpoints and showing a favorable safety profile. See our latest analysis for Definium Therapeutics. Definium Therapeutics shares have rallied strongly into these Voyage results, with a 7 day share price return of 12.88% and a 90 day share price return of 121.27%. The 1 year total shareholder return of...
NYSE:CRGY
NYSE:CRGYOil and Gas

Crescent Energy (CRGY) Could Be 19% Below Fair Value Following Its Dividend Decision

Crescent Energy dividend decision and why it matters Crescent Energy (CRGY) recently declared a total dividend of $0.12 per share, with an ex-dividend date of 17 August 2026. The consistent quarterly payouts since 2022 now sit alongside weaker dividend growth and earnings trends. See our latest analysis for Crescent Energy. Crescent Energy’s recent dividend news comes alongside strong share price momentum in 2026, with a 1-month share price return of 20.47% and a year to date share price...
NasdaqGS:HBNC
NasdaqGS:HBNCBanks

Horizon Bancorp (HBNC) Adds Two Directors, Is The Stock Still Undervalued?

Horizon Bancorp (HBNC) recently expanded its Board of Directors from 11 to 13 members, adding Nicholas J. Ritter and Charles W. Sulerzyski to the Class of 2027 and to the Horizon Bank board. See our latest analysis for Horizon Bancorp. At a share price of $20.28, Horizon Bancorp has seen modest short term share price softness, while its 90 day share price return of 10.64% and 1 year total shareholder return of 31.20% point to stronger underlying momentum. If this board refresh has you...
NasdaqCM:GSM
NasdaqCM:GSMMetals and Mining

Polysilicon Stocks Retail Investors Are Watching After New US Tariffs

Right now, tariffs and trade rules are reshaping the economics of polysilicon and solar grade silicon, turning supply chains into a live stress test for listed stocks. That disruption can create pricing power for some companies and fresh risks for others, which is why investors are watching this corner of the market so closely. This article walks through three screened stocks that appear particularly exposed to the latest policy shock. The three stocks highlighted below are just a starting...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

BeOne Medicines (ONC), What Is Behind The Fresh Attention Now?

BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this month. See our latest analysis for BeOne Medicines. Following the earnings beat and raised 2026 guidance, BeOne Medicines stock has picked up momentum, with an 18.31% 1 month share price return and a 19.57% 3 month share price return. That sits alongside an 18.12% 1 year total shareholder return...
NasdaqGS:ROIV
NasdaqGS:ROIVBiotechs

Is Roivant Sciences (ROIV) Fully Valued As First Quarter Results Show A Narrower Loss?

Why Roivant Sciences Earnings Matter For Shareholders Roivant Sciences (ROIV) reported first quarter 2026 results with sales of US$1.44 million compared to US$2.17 million a year earlier, while the net loss narrowed to US$189.84 million from US$223.36 million. See our latest analysis for Roivant Sciences. Roivant Sciences shares have gained momentum around the earnings release, with a 1-month share price return of 8.29% and a year to date share price return of 70.41%. The 1-year total...
NasdaqGS:CCNE
NasdaqGS:CCNEBanks

CNB Financial (CCNE) Declares Quarterly Dividend, Is The Stock Still Cheap?

CNB Financial (CCNE) drew fresh attention after its Board declared a quarterly cash dividend of $0.19 per share, payable on September 15, 2026, to shareholders of record on September 1, 2026. See our latest analysis for CNB Financial. At a share price of US$34.82, CNB Financial has seen its short term momentum build, with a 90 day share price return of 14.09% and a year to date share price return of 35.28%. The 1 year total shareholder return of 43.63% and 3 year total shareholder return of...
NYSE:TRLV
NYSE:TRLVPharmaceuticals

Trulieve Cannabis (TRLV) Could Be 47% Undervalued Following Its NYSE Debut

Why Trulieve Cannabis Stock Is Back In Focus After Its NYSE Debut Trulieve Cannabis (TRLV) drew fresh attention after ringing the New York Stock Exchange Closing Bell and becoming the first U.S. cannabis company to list on the NYSE. The move signals higher visibility and potentially wider investor access. The NYSE listing sits alongside Trulieve Cannabis operations that include 207 medical dispensaries, 5,000 employees, and 3.5 million square feet of cultivation and production capacity across...
NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

MannKind (MNKD) After Mixed Earnings Is The Stock Still Undervalued

Why MannKind's latest earnings matter for shareholders MannKind (MNKD) recently reported second quarter 2026 results that combined higher revenue with a shift back to losses. This mix of topline expansion and weaker profitability is now central to how investors assess the stock. See our latest analysis for MannKind. MannKind's recent earnings release has arrived after a period where the stock has swung between pressure and recovery, with a 25.23% 90 day share price return against a weaker...
NYSE:NFG
NYSE:NFGGas Utilities

National Fuel Gas (NFG) Files A Shelf Registration, Is It Still 9% Undervalued?

Shelf registration puts funding options on the table National Fuel Gas (NFG) has filed an omnibus shelf registration covering debt, common and preferred stock, depositary shares, stock purchase contracts and units. This filing refreshes the company’s ability to raise capital through multiple security types. See our latest analysis for National Fuel Gas. At a share price of US$83.37, National Fuel Gas has seen a 1-day share price return of 1.89% and a 30-day share price return of 3.00%. The...
NasdaqGM:TNGX
NasdaqGM:TNGXBiotechs

The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift

Tango Therapeutics, Inc. recently reported a wider net loss of US$55.34 million for the second quarter of 2026, filed a US$400 million at-the-market follow-on equity offering, and made several leadership changes including appointing a new Chairman and a future Chief Commercialization Officer. These moves point to a company aligning its capital-raising plans with the build-out of commercialization expertise as it prepares vopimetostat for later-stage development. Next, we will examine how the...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers

What Viridian Therapeutics’ Latest Earnings Mean For Investors Viridian Therapeutics (VRDN) reported its second quarter and six month results to June 30, 2026, giving investors fresh detail on revenue and losses that appear to be driving recent stock interest. Quarterly revenue was US$0.284 million compared with US$0.075 million a year earlier. Net loss for the period was US$127.12 million, with basic loss per share from continuing operations at US$1.05 compared with US$1 in the prior year...
NYSE:MDU
NYSE:MDUGas Utilities

How Investors Are Reacting To MDU (MDU) Dividend Hike And Reset Payout Ratio Target

In August 2026, MDU Resources Group’s board raised its quarterly dividend to US$0.145 per share, updated its long‑term dividend payout ratio target to 55%–65% of earnings, and set an October 1, 2026 payment date for shareholders of record on September 10, 2026. This combination of a higher cash payout and a lower target payout range highlights management’s focus on balancing income returns with earnings retention for future investment. Next, we’ll examine how the dividend increase and...
NYSE:PB
NYSE:PBBanks

The Bull Case For Prosperity Bancshares (PB) Could Change Following Spotlight On Its Dividend Profile

Recently, Prosperity Bancshares was highlighted for offering a 3.2% dividend yield, above both its banking peers and the S&P 500, with five years of consistent dividend increases supported by a payout ratio of about 40% of earnings. An interesting angle for investors is how this combination of above-average yield, measured dividend growth and a seemingly sustainable payout level is refocusing attention on Prosperity Bancshares’ income profile. We’ll now examine how Prosperity Bancshares’...
NYSE:CNMD
NYSE:CNMDMedical Equipment

CONMED (CNMD) Could Be 8% Overvalued Following Its Recent Rebound

Event context for CONMED and recent performance snapshot Recent commentary on CONMED (CNMD) highlights adoption of its AirSeal, Buffalo Filter, and BioBrace platforms alongside tariff and product specific growth risks. Investors are weighing this product mix against the stock’s recent share price moves. See our latest analysis for CONMED. At a share price of US$49.26, CONMED has seen its 30 day share price return of 14.03% and 90 day share price return of 33.10% contrast with a 1 year total...
NYSE:TBBB
NYSE:TBBBConsumer Retailing

BBB Foods (TBBB) Posts Strong Sales Growth, Is The Stock Fully Priced?

Why BBB Foods Stock Is Back In Focus After Earnings And Capital Plans BBB Foods (TBBB) is drawing attention after reporting second quarter and half year results that paired higher revenue with wider net losses, followed closely by a large shelf registration for potential share issuance. See our latest analysis for BBB Foods. The recent earnings update and US$1.53b shelf registration appear to have sharpened focus on BBB Foods, with the share price at US$48.06 after a 7 day share price return...
NasdaqGS:CSWC
NasdaqGS:CSWCCapital Markets

KKR Stock And 2 Private Credit Picks For Higher Rate Lending

Long term Treasury yields near multi decade highs are reshaping where credit risk feels most exposed. AI and tech stocks tied to heavy spending are being repriced as debt, not just growth stories, which is pulling attention toward listed private credit and alternative lenders. This article walks through three stocks from that universe that appear well positioned relative to these shocks and explains how their exposure to the news could matter for your portfolio. The three listed private...
NasdaqGS:DXPE
NasdaqGS:DXPETrade Distributors

Stronger Q2 2026 Earnings Might Change The Case For Investing In DXP Enterprises (DXPE)

DXP Enterprises reported past second-quarter 2026 results showing sales of US$576.46 million and net income of US$28.71 million, with both basic and diluted earnings per share from continuing operations higher than a year earlier. Over the first half of 2026, DXP’s higher sales and earnings, alongside prior commentary about strong long-term revenue and earnings-per-share expansion, highlight how its growth initiatives are translating into improved profitability. With this earnings strength...
NasdaqGM:ORKA
NasdaqGM:ORKABiotechs

Oruka Therapeutics (ORKA) Is Up 8.0% After Wider Q2 Net Losses - Has The Bull Case Changed?

In August 2026, Oruka Therapeutics, Inc. reported second-quarter and six-month results showing net losses of US$41.21 million and US$73.03 million, respectively, with basic loss per share from continuing operations rising to US$0.55 for the quarter and US$1.04 for the half year compared with the prior period. The results highlight that Oruka’s losses and loss per share have increased compared with a year earlier, sharpening investor focus on how the company is funding and pacing its...